Compare Linde PLC (LIN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Novavax Inc — how do they compare? Linde PLC trades at $512 (market cap $236.74B), while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: Linde PLC is far larger — about 182.1× Novavax Inc's market cap, and Linde PLC pays a 1.25% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| LIN | NVAX | |
|---|---|---|
Market Cap | $236.74B | $1.30B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $11.19 |
52-Week Low | $389.38 | $6.22 |
Enterprise Value | $259.10B | $800.50M |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $512.05, down 0.2% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with revenue growth to $34.0B in 2025. Recent Q1 2026 results showed EPS of $4.33 beating estimates, while analyst consensus remains strongly bullish with 89% buy ratings and a $564.80 price target.
LIN presents a compelling long-term investment with premium valuation metrics offset by exceptional profitability and dividend growth. Key risks include elevated debt levels (debt-to-asset ratio rising to 31.63% in 2025) and potential margin pressure from economic cycles. The current technical weakness may offer entry points for investors seeking quality industrial exposure with sustainable growth prospects.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
